A new NCPA study concludes that Congress must act to reduce the regulatory burden on pharmaceutical research and development.
Read more at NCPA's Health Policy Blog.
Research and commentary from a former senior executive in the U.S. Department of Health & Human Services
No comments:
Post a Comment